Capricor Therapeutics stock surges on FDA BLA review resumption

Capricor Therapeutics announced that the FDA has resumed its review of the Biologics License Application (BLA) for its lead product candidate. This news has led to a significant surge in the company's stock price as investors are optimistic about the potential approval. The resumption of the review indicates a positive step forward in the regulatory process, boding well for future product launch and revenue. Analysts view this as a breakthrough moment for Capricor and the related sector. Overall, the sentiment around Capricor is bullish, poised for further gains as developments progress.